Immune Regulation by CD55 in Chronic Beryllium Disease
Authors:
- 9 April 2026
- journal article
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 74 (10) , 1431-1439
Abstract
CD55 is an immune regulator that inhibits T cell activation and also binds to CD97, a molecule involved in immune cell migration and signaling. While CD55 expression is reduced in chronic beryllium disease (CBD), its functional role in disease pathogenesis remains unclear. We hypothesized that CD55 downregulation in peripheral blood mononuclear cells (PBMCs) contributes to heightened beryllium (Be)-specific immune responses in CBD. To test this, we characterized CD55 expression and function in PBMCs from individuals with CBD and beryllium sensitization (BeS), as well as in a human Be-specific T cell model. CD55, sCD55, and CD97 mRNA expression were quantified by qRT-PCR in PBMCs from CBD (n = 25), BeS (n = 36), and control (n = 7) subjects. BeSO4 stimulation was used to assess CD55, STAT1, JAK2, and TNF-α expression over time in CBD PBMCs (n = 8). Serum sCD55 was measured by ELISA in an independent cohort. Functional studies using anti-CD55 neutralizing antibodies and the JAK2 inhibitor TG101348 evaluated effects on TNF-α production and lymphocyte proliferation (BeLPT) in PBMCs, and IL-2 production in a Jurkat-Be cell model. CD55, sCD55, and CD97 were significantly downregulated in CBD PBMCs compared to BeS (P < .001). Serum sCD55 was also reduced in CBD (P < .05). BeSO4 stimulation further downregulated CD55 and upregulated STAT1. CD55 blockade increased TNF-α production and BeLPT responses in CBD (P < .001) and BeS (P < .05); these effects were reversed by JAK2 inhibition. In the Be-cell model, CD55 inhibition enhanced IL-2 production (P < .01), attenuated by JAK2 blockade. These findings suggest that CD55 downregulation amplifies Be-induced immune responses in CBD via JAK2/STAT1 signaling.Keywords
Funding Information
- National Institutes of Health (R01ES034767)
- National Institutes of Health (R01ES033678)
- National Institutes of Health (R21ES03637)
- Anne Theodore Foundation Breakthrough Sarcoidosis Initiative
This publication has 35 references indexed in Scilit:
- CD55 in cancer: Complementing functions in a non-canonical mannerCancer Letters, 2022
- Genomic biomarkers in chronic beryllium disease and sarcoidosisRespiratory Medicine, 2021
- Chronic Beryllium DiseaseChest, 2020
- p38 Mitogen-Activated Protein Kinase in beryllium-induced dendritic cell activationHuman Immunology, 2014
- Expression of CD55 and CD59 on peripheral blood cells from systemic lupus erythematosus (SLE) patientsCellular Immunology, 2010
- The Role of CD97 in Regulating Adaptive T-Cell Responses2010
- Membrane complement regulatory proteinsClinical Immunology, 2006
- Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravisExperimental Neurology, 2004
- Deletion of Decay-Accelerating Factor (CD55) Exacerbates Autoimmune Disease Development in MRL/lpr MiceThe American Journal of Pathology, 2002
- Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plantInternational Archives of Occupational and Environmental Health, 2001